Kim S H, Park Y N, Lim J H, Choi G H, Choi J S, Kim K S
Department of Surgery, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea.
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Eur J Surg Oncol. 2014 Aug;40(8):976-81. doi: 10.1016/j.ejso.2014.04.016. Epub 2014 May 23.
The 7th American Joint Committee on Cancer (AJCC) currently classifies combined hepatocellular-cholangiocarcinoma (cHCC-CC) and intrahepatic cholangiocarcinoma (ICC) into one category. Study outcomes comparing the two carcinomas have shown contrary results. This study was designed to compare the survival and prognostic factors of both carcinomas.
We retrospectively reviewed the medical records of 107 patients with cHCC-CC or ICC who underwent liver resection between January 2000 and December 2009.
Thirty patients (28%) were diagnosed with cHCC-CC, and 77 patients (72%) had ICC. Disease-free survival (DFS) was poorer in the cHCC-CC patients (six months), and the overall survival (OS) durations were similar (p = 0.477) between cHCC-CC (58 months) and ICC (45 months) patients. A tumor size larger than 5 cm, vascular invasion and lymph node (LN) metastasis were prognostic factors in all patients. However, tumor size and LN metastasis in cHCC-CC patients and carbohydrate antigen 19-9, differentiation and LN metastasis in ICC patients were found to be independent prognostic factors.
Patients with cHCC-CC showed poorer DFS and similar OS rates compared to those with ICC. Our study revealed different prognostic factors in cHCC-CC. To understand more accurately cHCC-CC's prognosis, difference of genetic characteristics and tumor biology should be further evaluated.
美国癌症联合委员会(AJCC)第7版目前将肝细胞胆管癌(cHCC-CC)和肝内胆管癌(ICC)归为同一类别。比较这两种癌症的研究结果显示出相互矛盾的结论。本研究旨在比较这两种癌症的生存率和预后因素。
我们回顾性分析了2000年1月至2009年12月期间接受肝切除术的107例cHCC-CC或ICC患者的病历。
30例(28%)患者被诊断为cHCC-CC,77例(72%)为ICC。cHCC-CC患者的无病生存期(DFS)较差(6个月),cHCC-CC患者(58个月)和ICC患者(45个月)的总生存期(OS)相似(p = 0.477)。肿瘤大小大于5 cm、血管侵犯和淋巴结(LN)转移是所有患者的预后因素。然而,cHCC-CC患者的肿瘤大小和LN转移以及ICC患者的糖类抗原19-9、分化程度和LN转移被发现是独立的预后因素。
与ICC患者相比,cHCC-CC患者的DFS较差,OS率相似。我们的研究揭示了cHCC-CC中不同的预后因素。为了更准确地了解cHCC-CC的预后,应进一步评估其基因特征和肿瘤生物学的差异。